vs
Side-by-side financial comparison of HeartSciences Inc. (HSCS) and TuHURA Biosciences, Inc. (HURA). Click either name above to swap in a different company.
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 150 countries and has employed 10000 people, as of 2024.
HSCS vs HURA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.4K | $0 |
| Net Profit | $-2.4M | $-6.8M |
| Gross Margin | 58.3% | — |
| Operating Margin | -85713.2% | — |
| Net Margin | -97179.4% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -12.9% | -12.8% |
| EPS (diluted) | $-0.85 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.4K | $0 | ||
| Q3 25 | $1.9K | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | $0 | $0 | ||
| Q3 24 | — | $0 | ||
| Q1 24 | $14.7K | $0 | ||
| Q4 23 | $3.9K | — | ||
| Q2 23 | $0 | — |
| Q4 25 | $-2.4M | $-6.8M | ||
| Q3 25 | $-2.1M | $-7.1M | ||
| Q2 25 | — | $-9.5M | ||
| Q1 25 | $-2.5M | $-6.7M | ||
| Q3 24 | — | $-5.6M | ||
| Q1 24 | $-1.6M | $-4.8M | ||
| Q4 23 | $-1.7M | — | ||
| Q2 23 | $-1.6M | — |
| Q4 25 | 58.3% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | 69.0% | — | ||
| Q4 23 | 61.0% | — | ||
| Q2 23 | — | — |
| Q4 25 | -85713.2% | — | ||
| Q3 25 | -98637.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -10376.7% | — | ||
| Q4 23 | -40254.9% | — | ||
| Q2 23 | — | — |
| Q4 25 | -97179.4% | — | ||
| Q3 25 | -108157.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -11182.4% | — | ||
| Q4 23 | -44830.2% | — | ||
| Q2 23 | — | — |
| Q4 25 | $-0.85 | $-0.13 | ||
| Q3 25 | $-1.58 | $-0.14 | ||
| Q2 25 | — | $-0.21 | ||
| Q1 25 | $-2.57 | $-0.15 | ||
| Q3 24 | — | $-0.54 | ||
| Q1 24 | $-3.01 | $-0.40 | ||
| Q4 23 | $-15.92 | — | ||
| Q2 23 | $-79.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0M | $3.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $20.9M |
| Total Assets | $6.0M | $27.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $3.6M | ||
| Q3 25 | $2.8M | $2.7M | ||
| Q2 25 | — | $8.5M | ||
| Q1 25 | $2.6M | $6.2M | ||
| Q3 24 | — | $3.0M | ||
| Q1 24 | $7.1M | $6.4M | ||
| Q4 23 | $100.1K | — | ||
| Q2 23 | $1.7M | — |
| Q4 25 | $4.2M | $20.9M | ||
| Q3 25 | $3.1M | $16.8M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | $1.8M | $9.9M | ||
| Q3 24 | — | $-2.8M | ||
| Q1 24 | $8.6M | $-6.1M | ||
| Q4 23 | $-1.6M | — | ||
| Q2 23 | $230.6K | — |
| Q4 25 | $6.0M | $27.4M | ||
| Q3 25 | $6.4M | $25.7M | ||
| Q2 25 | — | $34.6M | ||
| Q1 25 | $5.7M | $14.6M | ||
| Q3 24 | — | $4.1M | ||
| Q1 24 | $10.8M | $7.4M | ||
| Q4 23 | $2.4M | — | ||
| Q2 23 | $3.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-5.6M |
| Free Cash FlowOCF − Capex | — | $-5.6M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.3M | $-5.6M | ||
| Q3 25 | $-2.0M | $-11.1M | ||
| Q2 25 | — | $-6.2M | ||
| Q1 25 | $-1.6M | $-4.7M | ||
| Q3 24 | — | $-1.9M | ||
| Q1 24 | $-2.1M | $-3.8M | ||
| Q4 23 | $-988.2K | — | ||
| Q2 23 | $-1.9M | — |
| Q4 25 | — | $-5.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-6.3M | ||
| Q1 25 | — | $-4.8M | ||
| Q3 24 | — | — | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $-990.1K | — | ||
| Q2 23 | $-1.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -14352.1% | — | ||
| Q4 23 | -25388.2% | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | 59.8% | — | ||
| Q4 23 | 50.1% | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
